

C3
concl'd

that is phosphorylated when said receptor is bound by its natural antigen, thereby inhibiting phosphorylation of said mIg component.

9. (Reiterated) The method of Claim 1, wherein said antibody is monovalent.

10. (Reiterated) The method of Claim 1, wherein said antibody is divalent.

12. (Twice Amended) A method to desensitize a B cell antigen receptor, wherein said B cell antigen receptor has a transducer component consisting of an Ig α -Ig β dimer, and a membrane Ig (mIg) component, said method comprising contacting a B cell antigen receptor with a bi-specific antibody comprising:

a. a first portion which binds the extracellular domain of said transducer component of said B cell antigen receptor and: (1) causes a dissociation of said mIg component from said transducer component when said components are associated with each other prior to contact with said antibody; or (2) inhibits association of said mIg component with said transducer component when said components are dissociated from each other prior to contact with said antibody; and

b. a second portion which selectively binds to a cell surface molecule expressed by a cell which expresses said B cell antigen receptor; wherein said B cell antigen receptor remains competent to bind its antigen, and fails, or has a reduced ability, to transduce signals.

13. (Reiterated) The method of Claim 12, wherein said second portion binds to a cell surface molecule which is expressed by an autoreactive B cell.

14. (Reiterated) The method of Claim 12, wherein said second portion binds to an antigen binding region of said B cell antigen receptor.

18. (Twice Amended) The method of Claim 1, wherein said mIg component is selected from the group consisting of IgD and IgM.

19. (Reiterated) The method of Claim 1, wherein said B cell antigen receptor selectively binds to an antigen associated with an autoimmune disease.

20. (Reiterated) The method of Claim 1, wherein said B cell antigen receptor selectively binds to an antigen associated with a graft cell.

C6
1321. (Twice Amended) The method of Claim 1, wherein said B cell antigen receptor is expressed by a cell selected from the group consisting of an autoreactive B cell, a B cell comprising a B cell antigen receptor that selectively binds to an antigen on a graft, a B cell lymphoma and a chronic lymphocytic leukemia cell.

N.E.
Dupl. catz.
22. (Reiterated) The method of Claim 1, wherein said antibody is administered to a patient that has an autoimmune disease selected from the group consisting of rheumatoid arthritis, systemic lupus erythematosus, insulin dependent diabetes mellitus, multiple sclerosis, myasthenia gravis, Grave's disease, autoimmune hemolytic anemia, autoimmune thrombocytopenia purpura, Goodpasture's syndrome, pemphigus vulgaris, acute rheumatic fever, post-streptococcal glomerulonephritis, and polyarteritis nodosa.

30. (Reiterated) The method of Claim 1, wherein said antibody is administered to a patient by way of a therapeutic composition comprising a pharmaceutically acceptable carrier and said antibody.

31. (Reiterated) The method of Claim 30, wherein said therapeutic composition is administered *in vivo*.

32. (Reiterated) The method of Claim 30, wherein said therapeutic composition is administered *ex vivo*.

C7
18 23. (Twice Amended) The method of Claim 1, wherein said antibody is contacted with said B cell antigen receptor in an *in vitro* assay.